| HOME >> BIOLOGY >> TECHNOLOGY |
POCKETECG's automated analysis allows physicians to monitor large numbers of patients simultaneously and saves time by eliminating the need to analyze ECG tracings once the device reports that an abnormal event has taken place.
"We believe the merger of these two companies would create important synergies in the diagnosis, monitoring and potential treatment of heart failure patients, specifically in the area of arrhythmias and A-Fib," said Howard J. Leonhardt, Chairman, CEO and Chief Technology Officer, Bioheart. "The monitoring and management of patients experiencing arrhythmias and A-Fib represents one of the fastest-growing segments of the treatment market."
"We believe this acquisition, if completed, will deliver significant value for patients, physicians, and both companies," says Dr. Marcin Szumowski, CEO, MEDICALGORITHMICS.
ABOUT ELECTROCARDIOGRAMS (ECG)
An electrocardiogram (ECG) is a diagnostic test that measures the electrical activity of the heartbeat. Every time the heart beats, an electrical impulse called a wave travels through the heart, causing it to contract and pump blood flow through the heart muscle.
An ECG provides physicians with two critical pieces of information they can use to diagnose heart health. First, by measuring time intervals on the ECG, doctors can determine how long the electrical wave takes to pass through the heart, which indicates whether the electrical activity is normal or slow, fast or irregular. Second, ECGs enable physicians to measure the amount of electrical activity that passes through the heart muscle, which may indicate that parts of the heart muscle are too large or are being overworked.
ABOUT MEDICALGORITHMICS, LTD.
MEDICALGORITHMICS, Ltd. is a privately held high-technology company,
established in 2005. The Company is focused on development of
'/>"/>
| SOURCE Bioheart, Inc. Copyright©2008 PR Newswire. All rights reserved |